Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Synergy Names Chief Strategy Officer

This article was originally published in Scrip

Executive Summary

Synergy Pharmaceuticals Inc. has appointed Marino Garcia to the newly created role of executive vice president and chief strategy officer – effective immediately. Garcia has been senior vice president corporate development and part of the leadership team since he joined Synergy in 2014. Previously he was vice president of global business development at Aptalis Pharma (acquired by Forest Labs) and vice president of US commercial operations and new product development at Aspreva Pharmaceuticals (acquired by Vifor Pharmaceuticals). Earlier in his career, Garcia held various US and international leadership roles in companies like Eli Lilly & Co and Pfizer.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst